Eliyahou Et Al Harari Purchases 61,068 Shares of CapsoVision (NASDAQ:CV) Stock

CapsoVision, Inc. (NASDAQ:CV) major shareholder Eliyahou Et Al Harari acquired 61,068 shares of the stock in a transaction on Friday, July 17th. The stock was bought at an average cost of $6.73 per share, with a total value of $410,987.64. Following the completion of the transaction, the insider owned 3,343,119 shares in the company, valued at $22,499,190.87. This trade represents a 1.86% increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Major shareholders that own at least 10% of a company’s shares are required to disclose their transactions with the SEC.

Eliyahou Et Al Harari also recently made the following trade(s):

• On Wednesday, July 8th, Eliyahou Et Al Harari bought 81,300 shares of CapsoVision stock. The shares were bought at an average cost of $6.09 per share, for a total transaction of $495,117.00.
• On Friday, June 26th, Eliyahou Et Al Harari purchased 13,850 shares of CapsoVision stock. The stock was purchased at an average price of $7.35 per share, with a total value of $101,797.50.

CapsoVision Stock Up 0.2%

Shares of NASDAQ:CV opened at $6.63 on Thursday. The business’s 50 day moving average is $6.78 and its 200 day moving average is $6.28. The stock has a market cap of $331.23 million and a P/E ratio of -2.83. CapsoVision, Inc. has a 52-week low of $3.43 and a 52-week high of $15.37.

CapsoVision (NASDAQ:CV) last issued its earnings results on Thursday, May 14th. The company reported ($0.15) earnings per share for the quarter. The business had revenue of $2.79 million during the quarter.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of CapsoVision in a report on Monday, June 29th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $8.50.

Institutional Trading of CapsoVision

A number of hedge funds have recently bought and sold shares of CV. Geode Capital Management LLC increased its holdings in shares of CapsoVision by 34.1% in the 4th quarter. Geode Capital Management LLC now owns 154,264 shares of the company’s stock valued at $1,649,000 after acquiring an additional 39,231 shares during the period. State Street Corp lifted its stake in shares of CapsoVision by 340.7% during the 4th quarter. State Street Corp now owns 85,929 shares of the company’s stock worth $919,000 after purchasing an additional 66,429 shares during the last quarter. Bank of New York Mellon Corp bought a new stake in CapsoVision during the first quarter valued at about $359,000. Citadel Advisors LLC purchased a new position in CapsoVision in the third quarter valued at about $115,000. Finally, Bank of America Corp DE grew its stake in CapsoVision by 528.9% in the first quarter. Bank of America Corp DE now owns 22,238 shares of the company’s stock valued at $162,000 after purchasing an additional 18,702 shares during the last quarter.

About CapsoVision

CapsoVision, Inc (NASDAQ: CV) is a medical device company specializing in advanced capsule endoscopy systems for gastrointestinal diagnostics. The company’s flagship product, the CapsoCam® Plus System, features a swallowable, tether-free capsule equipped with four side-viewing cameras that capture high-resolution, 360-degree images of the small intestine. By storing images internally rather than transmitting data wirelessly, CapsoCam Plus enables patients to maintain normal daily activities during the procedure and reduces the risk of signal loss or image drop-out.

In addition to its capsule hardware, CapsoVision offers CapsoCloud®, a secure, cloud-based platform that streamlines image retrieval, storage and reporting.